MARKET

NVAX

NVAX

Novavax Inc
NASDAQ
8.47
+0.43
+5.35%
After Hours: 8.46 -0.01 -0.12% 19:59 11/22 EST
OPEN
8.06
PREV CLOSE
8.04
HIGH
8.62
LOW
8.00
VOLUME
4.79M
TURNOVER
--
52 WEEK HIGH
23.86
52 WEEK LOW
3.532
MARKET CAP
1.36B
P/E (TTM)
-3.7526
1D
5D
1M
3M
1Y
5Y
1D
Trump Trade: Trump Media considers developing crypto payment service
TipRanks · 12h ago
Trump expected to pick Martin Makary to head FDA, Reuters reports
TipRanks · 13h ago
Matt Gaetz Withdraws. Why That Might Be Bad News for RFK.
Barron‘s · 1d ago
Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA vaccine official says RFK Jr. nomination is a chance for scientist to make the case for vaccines"
Benzinga · 1d ago
CDC warns against a spike in COVID, flu cases
Seeking Alpha · 2d ago
U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks
Benzinga · 2d ago
Novavax to Present at Jefferies London Conference
TipRanks · 2d ago
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
Barron‘s · 3d ago
More
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Webull offers Novavax Inc stock information, including NASDAQ: NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.